-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Jimin Trust Group announced that in response to the impact of the new crown Omicron variant on the prevention and control of the global new crown epidemic, Dr.
Deng Sujun, from the Macromolecular Innovation Research Institute of Jimin Trust R&D Center, led the team to carry out a Investigated the efficacy of JMB2002 antibody on Omicron, and worked with the team of Professor Xu Huaqiang and Dr.
Yin Wanchao of Shanghai Institute of Materia Medica, Chinese Academy of Sciences to analyze the structure of Omicron spike protein binding receptor ACE2 and the binding of JMB2002 to Omicron Thorn The structure of the spike protein revealed the biological mechanism of rapid spread and immune escape of Omicron at the molecular level, and expounded the effectiveness of JMB2002 on Omicron from the mechanism.
The corresponding research results have been published in the bioRxiv preprint
.
The latest research results of Jimin Trust show that JMB2002 exhibits good biological activity and potential virus-inhibiting effect in the neutralization experiment of Omicron pseudovirus
.
This result is encouraging in a situation where most of the neutralizing antibodies under development on the market are ineffective or have a reduced effect on Omicron
.
One of the reasons for the enhanced transmission of the Omicron variant is that the receptor-binding region of its spike protein and its receptor ACE2 are significantly enhanced compared to the wild type, and the development of specific therapeutic antibodies against the Omicron variant is imminent.
.
Jimin Trusted researchers found that the binding ability of JMB2002 to the spike protein of the Omicron variant was 4 times higher than that of the wild-type strain
.
The joint team of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Jimin Trust successfully analyzed the structure of the spike protein of Omicron variant strain and the specific therapeutic antibody JMB2002.
From the obtained structure, scientists found that the JMB2002 antibody fragment is a novel The conformational binding of the antibody on the back of the RBD receptor-binding epitope is a novel mechanism of action
.
Combined with biochemical and antiviral neutralization experiments, this joint study expounds the molecular mechanism of antibody JMB2002 with broad-spectrum anti-COVID-19
.
JMB2002 will complete the domestic phase I clinical study in June 2021, and the tolerability, safety, pharmacokinetic characteristics and immunogenicity in healthy subjects have all reached the expected results
.
In March 2021, JMB2002 injection was approved by the FDA for clinical trials in the United States
.
At present, Jimin Trust has completed the preparation of 2000 liters of JMB2002 clinical drug, and can start the next clinical research at any time
.
Deng Sujun, from the Macromolecular Innovation Research Institute of Jimin Trust R&D Center, led the team to carry out a Investigated the efficacy of JMB2002 antibody on Omicron, and worked with the team of Professor Xu Huaqiang and Dr.
Yin Wanchao of Shanghai Institute of Materia Medica, Chinese Academy of Sciences to analyze the structure of Omicron spike protein binding receptor ACE2 and the binding of JMB2002 to Omicron Thorn The structure of the spike protein revealed the biological mechanism of rapid spread and immune escape of Omicron at the molecular level, and expounded the effectiveness of JMB2002 on Omicron from the mechanism.
The corresponding research results have been published in the bioRxiv preprint
.
The latest research results of Jimin Trust show that JMB2002 exhibits good biological activity and potential virus-inhibiting effect in the neutralization experiment of Omicron pseudovirus
.
This result is encouraging in a situation where most of the neutralizing antibodies under development on the market are ineffective or have a reduced effect on Omicron
.
One of the reasons for the enhanced transmission of the Omicron variant is that the receptor-binding region of its spike protein and its receptor ACE2 are significantly enhanced compared to the wild type, and the development of specific therapeutic antibodies against the Omicron variant is imminent.
.
Jimin Trusted researchers found that the binding ability of JMB2002 to the spike protein of the Omicron variant was 4 times higher than that of the wild-type strain
.
The joint team of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Jimin Trust successfully analyzed the structure of the spike protein of Omicron variant strain and the specific therapeutic antibody JMB2002.
From the obtained structure, scientists found that the JMB2002 antibody fragment is a novel The conformational binding of the antibody on the back of the RBD receptor-binding epitope is a novel mechanism of action
.
Combined with biochemical and antiviral neutralization experiments, this joint study expounds the molecular mechanism of antibody JMB2002 with broad-spectrum anti-COVID-19
.
JMB2002 will complete the domestic phase I clinical study in June 2021, and the tolerability, safety, pharmacokinetic characteristics and immunogenicity in healthy subjects have all reached the expected results
.
In March 2021, JMB2002 injection was approved by the FDA for clinical trials in the United States
.
At present, Jimin Trust has completed the preparation of 2000 liters of JMB2002 clinical drug, and can start the next clinical research at any time
.
